Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results

Advertisement
Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results

lilly oct4

Markets Insider

Advertisement
Advertisement
  • On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company's stock rose 3% on the news.
  • The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.
  • The late-stage trial for this drug is expected to be completed in 2021.
  • This drug has to potential to boost Lilly's growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men's health and musculoskeletal fields.

Business Insider Intelligence Exclusive FREE Report: The 5 Ways AI Will Change U.S. Healthcare

NOW WATCH: 3 compelling reasons why we haven't found aliens yet

{{}}
Next StorySOCGEN: Hedge funds are making historic bets that remind us of the dotcom bubble right before it burst